Dynamiker Biotechnology (Tianjin) Co., Ltd.

Dynamiker Biotechnology was founded in March 2014 and is located in Tianjin Eco-city. It is committed to the R&D, production and global sales of innovative in vitro diagnostic products for invasive fungal diseases (IFD), new coronavirus diseases and other pathogenic microorganisms. We are gradually becoming the leading enterprise with competitive advantages in the joint detection and precision diagnosis industry segments.

Dynamiker Biotechnology has established academician expert workstation, postdoctoral workstation, Tianjin key laboratory, Tianjin enterprise technology center. Dynamiker has presided over more than 20 national and Tianjin municipal scientific and technological major projects, obtained 67 nationally authorized patents and 62 medical device registration certificates. Dynamiker’s products have been introduced into more than 2,000 key hospitals and Independent laboratories in China, and have been clinically applied in key hospitals in nearly 100 countries overseas. We have been participating in the establishment and development of the National Fungal Disease surveillance network, led by the National Health Commission, and set up the Research Center for "Fungal Disease Diagnosis and Treatment ".

We have six core platforms, which are Ag/Ab preparation, molecular diagnostic, immunology, POCT, TAL (horseshoe crab) R&D and Clinical Transformation. With the support of six core technology platforms, more and more new products are gradually introduced, like a series of fungal detection products covering a variety of fungal types, including Panfungal screening test, Invasive Aspergillosis, Invasive Candidiasis, Cryptococcosis, Mucomycosis, PJP, Fusarium, Talaromyces marneffei., a series of COVID-19 detection products developed during the fight against the epidemic, and bacterial drug resistance detection products developed in response to the call of the World Health Organization. All products are CE-IVD under ISO13485, More than 50 peer-reviewed papers and studies had proved the good quality of Dynamiker’s kits.

With the constatction of “One Belt, One Road”, Dynamiker Biotechnology fungal testing products have entered more than 500 key hospitals in more than 100 countries and regions in Asia, Europe, South America, Africa, and the Middle East by virtue of their strong competitive advantages. The hospital has completed the diagnosis of hundreds of millions of patients with fungal infection, contributing Chinese strength to the development of fungal detection medicine in the world.

As the sole partner of GAFFI in China, Dynamiker Biotechonology actively cooperates with GAFFI to promote the establishment of international reference laboratories and industry standards. Adhere to the improvement of innovative technology and product quality, actively participate in industry-university-research and international project cooperation, and carry out strategic cooperation with Pfizer China to jointly promote the precise use of clinical antifungal drugs. In addition, Dynamiker innovative products have been included in the WHO product procurement list.